Anteris Technologies Global Corp. filed a definitive proxy statement on November 9, 2026, calling stockholders to a 2026 Annual Meeting on December 2, 2026, at 4:00 p.m. Central time, with a broad agenda spanning director elections, auditor ratification, and numerous equity award approvals.

Key Highlights

  • Annual Meeting date: December 2, 2026, at 4:00 p.m. Central time, with an in-person option at the InterContinental Sydney, 16 Phillip Street, Sydney, NSW, 2000, Australia.
  • Record date: October 29, 2026 (close of business), determines stockholder eligibility to vote.
  • Director election (Proposal One): Stockholders are asked to elect David St Denis and Stephen Denaro as Class II directors, each to serve until the 2029 annual meeting.
  • Auditor ratification (Proposal Two): Stockholders are asked to ratify the appointment of KPMG as independent registered public accounting firm for fiscal year ending December 31, 2026.
  • CEO equity grants proposed: Proposals Three, Eight, and Seventeen seek approval for 629,921 RSUs, 1,200,000 Option Rights, and 800,000 PSUs, respectively, for CEO Wayne Paterson.
  • 21 total proposals: The agenda includes equity award approvals covering RSUs, nonqualified option rights, and performance-based RSUs for executives and non-employee directors, as well as an amendment to previously granted RSU terms under the Equity Plan.
  • CDI holder voting: Holders of CHESS Depositary Interests may not vote electronically or in person at the meeting and must direct CHESS Depositary Nominees Pty Ltd to vote their underlying shares in advance.

Anteris Technologies' 2026 Proxy Puts Extensive Equity Program to Stockholder Vote

Anteris Technologies Global Corp. (NASDAQ:AVR), a medical device company, filed a definitive Schedule 14A proxy statement on November 9, 2026, covering 21 separate proposals for its 2026 Annual Meeting. The meeting is scheduled for December 2, 2026, and may be attended either in person at the InterContinental Sydney in Australia or via live webcast. Only stockholders of record as of October 29, 2026, are entitled to vote, according to the filing.

Beyond the routine items of electing two Class II directors and ratifying KPMG as the company's independent auditor for fiscal year ending December 31, 2026, the proxy discloses a wide range of equity compensation proposals. Under Proposal Three, stockholders are asked to approve 629,921 restricted stock units for CEO Wayne Paterson related to his 2025 employment. Proposals Eight and Seventeen seek approval for 1,200,000 Option Rights and 800,000 performance-based RSUs for Paterson for 2026, respectively. President David St Denis is the subject of Proposals Four, Seven, and Eighteen, covering 314,960 RSUs tied to 2025 service, 414,000 Option Rights for 2026, and 485,000 PSUs for 2026.

Non-employee directors are also addressed: Proposals Six, Nine, Ten, Eleven, and Twelve each propose grants of nonqualified Option Rights valued between $235,000 and $250,000 in grant date value to individual directors, including John Seaberg, Gregory Moss, David Roberts, Stephen Denaro, and Susan Knight, under the Non-Employee Director Compensation Policy. Proposals Thirteen, Fourteen, and Fifteen propose additional Option Rights valued at $220,000 each to David Roberts, Gregory Moss, and Susan Knight as awards related to their board appointments. Proposal Sixteen asks stockholders to approve amendments to terms of RSUs previously granted under the Anteris Technologies Global Corp. Equity Incentive Plan. All equity proposals are submitted for the purposes of Australian Securities Exchange Listing Rule 10.14, reflecting the company's dual-listed structure. The proxy also notes that CDI holders must direct CHESS Depositary Nominees Pty Ltd in advance of the meeting if they wish their votes to be counted.

What Was Disclosed

Anteris Technologies Global Corp. filed a definitive proxy statement for its 2026 Annual Meeting, disclosing 21 proposals covering director elections, KPMG auditor ratification, and multiple equity award approvals for executives and non-employee directors under both NASDAQ and ASX listing requirements.